↓ Skip to main content

Dove Medical Press

Article Metrics

Epileptic seizure after treatment with thiocolchicoside

Overview of attention for article published in Therapeutics and Clinical Risk Management, August 2009
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (55th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (51st percentile)

Mentioned by

wikipedia
4 Wikipedia pages

Citations

dimensions_citation
9 Dimensions

Readers on

mendeley
33 Mendeley
Title
Epileptic seizure after treatment with thiocolchicoside
Published in
Therapeutics and Clinical Risk Management, August 2009
DOI 10.2147/tcrm.s4823
Pubmed ID
Authors

Pedro Giavina-Bianchi

Abstract

Adverse drug reactions are important determinants of inpatient and outpatient morbidity. Thiocolchicoside is a semisynthetic derivate of naturally occurring colchicoside, which is largely used in humans as a centrally acting muscle relaxant. Epileptic seizures after thiocolchicoside intake have been reported in individuals with a history of epilepsy, acute brain injury or possible blood-brain barrier disruption.

Mendeley readers

The data shown below were compiled from readership statistics for 33 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
France 1 3%
Unknown 32 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 6 18%
Student > Master 6 18%
Student > Ph. D. Student 4 12%
Other 4 12%
Professor 3 9%
Other 6 18%
Unknown 4 12%
Readers by discipline Count As %
Medicine and Dentistry 7 21%
Agricultural and Biological Sciences 6 18%
Pharmacology, Toxicology and Pharmaceutical Science 4 12%
Neuroscience 2 6%
Social Sciences 1 3%
Other 3 9%
Unknown 10 30%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 February 2022.
All research outputs
#6,861,532
of 21,173,213 outputs
Outputs from Therapeutics and Clinical Risk Management
#381
of 1,215 outputs
Outputs of similar age
#98,994
of 323,258 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#13
of 27 outputs
Altmetric has tracked 21,173,213 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,215 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.1. This one has gotten more attention than average, scoring higher than 59% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 323,258 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 55% of its contemporaries.
We're also able to compare this research output to 27 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 51% of its contemporaries.